Table 4.

Efficacy Results of Nivolumab as Second-Line Treatment of Metastatic Squamous NSCLC.

Efficacy	Nivolumab (n = 135)	Docetaxel (n = 137)
Prespecified Interim Analysis
Events (%)	86 (64%)	113 (82%)
Median survival in months (95% CI)	9.2 (7.3, 13.3)	6.0 (5.1, 7.3)
p-Value a	0.00025
Hazard ratio (95% CI) b	0.59 (0.44, 0.79)

^a p-Value is derived from a log-rank test stratified by region and prior to paclitaxel use; the corresponding O’Brien-Fleming efficacy boundary significance level is 0.0315; ^b Derived from a stratified proportional hazards model.